IntelliCell BioSciences Joins Forces With Dr. James Andrews's Research and Educational Foundation
March 12 2014 - 2:30PM
Marketwired
IntelliCell BioSciences Joins Forces With Dr. James Andrews's
Research and Educational Foundation
NEW YORK, NY--(Marketwired - Mar 12, 2014) - IntelliCell
Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous vascular
cells (SVCs) derived from the blood vessels found in adipose
tissue, announced today that it has signed a license agreement with
Dr. James Andrews's Research and Education Foundation (AREF) in
Gulf Breeze, Florida for the installation of its cGTP Cellular
Processing Lab for the manufacturing of Stromal Vascular Fraction
Cells (SVFC).
IntelliCell's Chief Executive Officer, Dr. Steven Victor,
remarked, "This is a huge step for IntelliCell BioScienses in the
fields of orthopedic and sports medicine. IntelliCell's SVF
cellular product has helped many professional and non-professional
athletes with their injuries, allowing them to return to their
careers and everyday life. With Dr. Andrews on board we will
be able to advance the research and science of the SVF cellular
product in the fields of orthopedic and sports medicine. We at
IntelliCell believe Dr. Andrews's world-class experience and
knowledge is unparalleled in the arena of treating injured
athletes, and with Dr. Andrews' guidance IntelliCell should be able
to make significant inroads."
As the new Chairman of the IntelliCell Orthopedic Cellular
Therapy Advisory Board, Dr. James Andrews stated, "We at the
Andrews's Research and Educational Foundation have recently joined
forces with Intelicell BioSciences to participate in their
autologous stem cell research. We are excited at the opportunity of
developing a first class biological laboratory at our facility in
conjunction with Intelicell BioSciences that will allow us to
continue our effort towards excellence in clinical stem cell
therapy research."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using adult
autologous stromal vascular fraction cells (SVFCs) derived from the
blood vessels in the adult adipose tissue. IntelliCell Biosciences
has developed its own patented technology and protocol to separate
adult autologous vascular cells from adipose tissue without the use
of enzymes. IntelliCell will also be seeking to develop
technology-licensing agreements with technology developers,
universities, and international business entities.
About Dr. James Andrews
Dr. James Andrews is internationally known and recognized for
his scientific and clinical research contributions in knee,
shoulder and elbow injuries, as well as his skill as an orthopedic
surgeon.
Dr. Andrews is a founding partner and medical director for the
Andrews Institute in Gulf Breeze, Florida. In addition, he is a
founding member of the American Sports Medicine Institute
(ASMI).
Dr. Andrews has been the mentor for more than 250
orthopedic/sports medicine fellows and more than 45 primary care
sports medicine fellows. Involved in education and research in
sports medicine and orthopedic surgery, he has made major
presentations on every continent, and has authored numerous
scientific articles and books.
Forward-Looking Statements
Certain statements set forth in this press release constitute
"forward-looking statements." Forward-looking statements include,
without limitation, any statement that may predict, forecast,
indicate, or imply future results, performance or achievements, and
may contain the words "estimate," "project," "intend," "forecast,"
"anticipate," "plan," "planning," "expect," "believe," "will
likely," "will reach," "will change," "will soon," "should,"
"could," "would," "may," "can" or words or expressions of similar
meaning. Such statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause the
company's actual results and financial position to differ
materially from those included within the forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to
grow its business. Actual results may differ materially from the
results predicted and reported results should not be considered as
an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited
operating history, the limited financial resources, domestic or
global economic conditions, activities of competitors and the
presence of new or additional competition, and changes in Federal
or State laws. More information about the potential factors that
could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact: IntelliCell BioSciences, Inc. Investor Relations Anna
Rhodes Email Contact (646) 576-8308